دورية أكاديمية
The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men.
| العنوان: | The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men. |
|---|---|
| المؤلفون: | Nahon KJ; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands., Janssen LGM; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands., Sardjoe Mishre ASD; Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden, the Netherlands., Bilsen MP; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands., van der Eijk JA; Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden, the Netherlands., Botani K; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands., Overduin LA; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands., Ruiz JR; Department of Physical Education and Sport, Faculty of Sport Sciences, PROFITH 'PROmoting FITness and Health through physical activity' research group, Sport and Health University Research Institute (iMUDS), University of Granada, Granada, Spain., Burakiewicz J; Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden, the Netherlands., Dzyubachyk O; Department of Radiology, Division of Image Processing (LKEB), Leiden University Medical Center, Leiden, the Netherlands., Webb AG; Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden, the Netherlands., Kan HE; Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden, the Netherlands., Berbée JFP; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands., van Klinken JB; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.; Laboratory Genetic Metabolic Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology and Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.; Core Facility Metabolomics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., van Dijk KW; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands., van Weeghel M; Laboratory Genetic Metabolic Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology and Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.; Core Facility Metabolomics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Vaz FM; Laboratory Genetic Metabolic Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology and Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.; Core Facility Metabolomics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Coskun T; Department of Diabetes/Endocrine, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA., Jazet IM; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands., Kooijman S; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands., Martinez-Tellez B; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.; Department of Physical Education and Sport, Faculty of Sport Sciences, PROFITH 'PROmoting FITness and Health through physical activity' research group, Sport and Health University Research Institute (iMUDS), University of Granada, Granada, Spain., Boon MR; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands., Rensen PCN; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands. |
| المصدر: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Nov; Vol. 22 (11), pp. 2032-2044. Date of Electronic Publication: 2020 Jul 29. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Wiley-Blackwell, c1999- |
| مواضيع طبية MeSH: | Adipose Tissue, Brown*/metabolism , Energy Metabolism*, Acetanilides ; Asian People ; Cold Temperature ; Cross-Over Studies ; Humans ; Male ; Thermogenesis ; Thiazoles |
| مستخلص: | Aim: To compare the effects of cold exposure and the β3-adrenergic receptor agonist mirabegron on plasma lipids, energy expenditure and brown adipose tissue (BAT) activity in South Asians versus Europids. Materials and Methods: Ten lean Dutch South Asian (aged 18-30 years; body mass index [BMI] 18-25 kg/m 2 ) and 10 age- and BMI-matched Europid men participated in a randomized, double-blinded, cross-over study consisting of three interventions: short-term (~ 2 hours) cold exposure, mirabegron (200 mg one dose p.o.) and placebo. Before and after each intervention, we performed lipidomic analysis in serum, assessed resting energy expenditure (REE) and skin temperature, and measured BAT fat fraction by magnetic resonance imaging. Results: In both ethnicities, cold exposure increased the levels of several serum lipid species, whereas mirabegron only increased free fatty acids. Cold exposure increased lipid oxidation in both ethnicities, while mirabegron increased lipid oxidation in Europids only. Cold exposure and mirabegron enhanced supraclavicular skin temperature in both ethnicities. Cold exposure decreased BAT fat fraction in both ethnicities. After the combination of data from both ethnicities, mirabegron decreased BAT fat fraction compared with placebo. Conclusions: In South Asians and Europids, cold exposure and mirabegron induced beneficial metabolic effects. When combining both ethnicities, cold exposure and mirabegron increased REE and lipid oxidation, coinciding with a higher supraclavicular skin temperature and lower BAT fat fraction. (© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.) |
| References: | J Clin Lipidol. 2017 Jul - Aug;11(4):920-928.e2. (PMID: 28625343) Endocrinology. 2004 Jan;145(1):269-80. (PMID: 14551227) Circulation. 2004 Aug 24;110(8):948-54. (PMID: 15302798) Lancet. 1991 Feb 16;337(8738):382-6. (PMID: 1671422) J Clin Invest. 2013 Jan;123(1):215-23. (PMID: 23221344) Indian J Pediatr. 2000 Aug;67(8):571-4. (PMID: 10984997) Diabetes. 2014 Mar;63(3):1093-102. (PMID: 24353181) Diabetes. 2005 Oct;54(10):2838-43. (PMID: 16186383) Magn Reson Med. 2005 Oct;54(4):1032-9. (PMID: 16142718) IEEE Trans Med Imaging. 2010 Jan;29(1):196-205. (PMID: 19923044) Circ Res. 2016 Jan 8;118(1):173-82. (PMID: 26837747) Nat Commun. 2015 Mar 10;6:6356. (PMID: 25754609) Magn Reson Med. 2004 Jan;51(1):35-45. (PMID: 14705043) Front Endocrinol (Lausanne). 2020 Jan 09;10:898. (PMID: 31998233) Sci Rep. 2017 Sep 5;7(1):10530. (PMID: 28874709) Front Neuroinform. 2014 Jan 16;7:50. (PMID: 24474917) Am J Physiol Endocrinol Metab. 2014 Oct 15;307(8):E653-63. (PMID: 25139049) J Magn Reson Imaging. 2007 Oct;26(4):1153-61. (PMID: 17896369) J Pharmacol Toxicol Methods. 2017 Sep;87:74-81. (PMID: 28434969) J Clin Invest. 1982 May;69(5):1119-25. (PMID: 7040473) Sci Rep. 2017 Aug 8;7(1):7558. (PMID: 28790443) Trends Endocrinol Metab. 2018 May;29(5):326-337. (PMID: 29588112) N Engl J Med. 2017 Jul 6;377(1):13-27. (PMID: 28604169) Int J Med Inform. 2019 Jun;126:9-18. (PMID: 31029269) Cell Metab. 2018 Oct 2;28(4):644-655.e4. (PMID: 30033199) PLoS One. 2014 Jun 12;9(6):e98822. (PMID: 24922545) Clin Chem. 1972 Jun;18(6):499-502. (PMID: 4337382) Br J Pharmacol. 1996 Aug;118(8):2023-8. (PMID: 8864538) Physiol Rev. 2004 Jan;84(1):277-359. (PMID: 14715917) J Clin Invest. 2013 Aug;123(8):3395-403. (PMID: 23867626) J Clin Endocrinol Metab. 2015 Nov;100(11):4249-56. (PMID: 26308293) J Appl Physiol Respir Environ Exerc Physiol. 1983 Aug;55(2):628-34. (PMID: 6618956) J Clin Invest. 2020 May 1;130(5):2209-2219. (PMID: 31961826) Diabetes. 2006 Nov;55(11):3053-60. (PMID: 17065342) J Clin Invest. 2020 May 1;130(5):2319-2331. (PMID: 31961829) Cell Metab. 2014 Sep 2;20(3):396-407. (PMID: 25127354) J Clin Endocrinol Metab. 2019 Feb 1;104(2):465-486. (PMID: 30137523) Diabetes. 2013 Jun;62(6):1783-90. (PMID: 23704519) J Magn Reson Imaging. 2018 Apr;47(4):936-947. (PMID: 28801960) Diabetes Obes Metab. 2020 Nov;22(11):2032-2044. (PMID: 32558052) J Clin Invest. 2013 Aug;123(8):3404-8. (PMID: 23867622) JAMA. 2009 May 27;301(20):2129-40. (PMID: 19470990) Diabetes. 2018 Oct;67(10):2113-2125. (PMID: 29980535) Orphanet J Rare Dis. 2019 Feb 7;14(1):30. (PMID: 30732635) J Lipid Res. 2016 Aug;57(8):1447-54. (PMID: 27284103) Am J Physiol. 1997 Apr;272(4 Pt 2):R1178-88. (PMID: 9140018) Nat Cell Biol. 2013 Jun;15(6):659-67. (PMID: 23624403) Cell Metab. 2015 Jan 6;21(1):33-8. (PMID: 25565203) Magn Reson Med. 2005 Sep;54(3):636-44. (PMID: 16092103) Nutrients. 2013 Jul 16;5(7):2708-33. (PMID: 23863826) Physiol Behav. 2012 Sep 10;107(2):252-61. (PMID: 22877870) J Am Coll Dent. 2014 Summer;81(3):14-8. (PMID: 25951678) Physiol Behav. 2006 Jul 30;88(4-5):489-97. (PMID: 16797616) J Lipid Res. 2015 Jan;56(1):51-9. (PMID: 25351615) Int J Obes (Lond). 2016 Apr;40(4):633-8. (PMID: 26568151) Nature. 2003 Mar 13;422(6928):173-6. (PMID: 12629551) Curr Opin Lipidol. 2016 Jun;27(3):242-8. (PMID: 27023630) Lancet Diabetes Endocrinol. 2014 Mar;2(3):210-7. (PMID: 24622751) Int J Obes (Lond). 2007 Apr;31(4):692-9. (PMID: 17224929) |
| معلومات مُعتمدة: | 2015.81.1808 International Diabetes Research Foundation Fellowship; CVON2014-02 ENERGISE and International Netherlands CardioVascular Research Initiative: 'the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organisation for Health Research and Development and the Royal Netherlands Academy of Sciences'; CVON2017-20 GENIUS-II International Netherlands CardioVascular Research Initiative: 'the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organisation for Health Research and Development and the Royal Netherlands Academy of Sciences'; 602485 International European Union's Seventh Framework Programme for research, technological development and demonstration; 2009T038 International European Research Council (NOMA-MRI) PCNR is an Established Investigator of the Netherlands Heart Foundation |
| فهرسة مساهمة: | Keywords: South Asian; brown adipose tissue; energy expenditure; lipid metabolism; metabolic disease; mirabegron |
| المشرفين على المادة: | 0 (Acetanilides) 0 (Thiazoles) MVR3JL3B2V (mirabegron) |
| تواريخ الأحداث: | Date Created: 20200620 Date Completed: 20210624 Latest Revision: 20221207 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC7771034 |
| DOI: | 10.1111/dom.14120 |
| PMID: | 32558052 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1463-1326 |
|---|---|
| DOI: | 10.1111/dom.14120 |